For Some VCs And Execs, Familiarity Breeds More Start-Ups
This article was originally published in Start Up
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.
You may also be interested in...
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
Approvals jumped, venture retrenched and dealmakers expanded on 2010’s creativity. Pharma’s thirst for payer-friendly innovation and emerging markets infrastructure pushed M&A valuations skyward, and threw VCs and drugmakers closer together. The year 2011 was also when we said goodbye to Lipitor, hello to the euro crisis, and “see you soon” to biosimilars.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.